{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028908","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.226220+00:00","generated_at":"2026-06-22T04:19:25.574611+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lyell Immunopharma Q3 net loss $70.3M; GSK ends collaboration; LYL797 data delayed to H1 2024","bullets":["Net loss $70.3M vs $48.9M YoY; non-GAAP net loss $43.7M vs $35.7M.","Cash $750.7M as of Sep 30, 2022; funding extends into 2026.","GSK terminates NY-ESO-1 programs LYL132/LYL331 effective Dec 24, 2022; not due to safety/efficacy.","IND cleared for LYL845 TIL therapy; initial data expected 2024.","LYL797 enrollment slower; initial data now expected first half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028908","json":"https://secwatch.observer/filing/0001628280-22-028908.json","markdown":"https://secwatch.observer/filing/0001628280-22-028908.md","text":"https://secwatch.observer/filing/0001628280-22-028908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/0001628280-22-028908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/lyel-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:19:25.574611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e95a46eec28987301aa08f9f3366ba90b349a5e","claim":"Lyell Immunopharma, Inc. reported financial results for third quarter of 2022.","evidence_excerpt":"On November 8, 2022, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/0001628280-22-028908-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}